In a major healthcare fraud enforcement action, Veloxis Pharmaceuticals will pay over million and accept a stringent deferred prosecution agreement ...
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bac...
Senior secured term loan of up to CHF 250 million with a 5‑year maturity at a fixed 7% interest rate First tranche will fully refinance the existing...
Q1 2026 Group performance Comparable order intake growth 6% Group sales of EUR 3.9 billion, reflecting 4% increase in comparable sales Income ...
Financial performance Q1 2026 reported sales increased by 32% at CER, positively impacted by a provision reversal related to the 340B Drug Prici...
Highly potent drugs now account for over 30% of the global pipeline, with more than 1,000 molecules in development — Axplora’s investments in...
Expands Agilent’s pathology portfolio through addition of highly complementary antibody, reagent and instrument business with annual double-digit...
Cure Rare Disease (CRD), a non-profit biotechnology organization, announced a landmark partnership with the LGMD2L Foundation. This collaboration i...
-Financing led by Forbion, joined by Sanofi and existing investors Medicxi, Pitango, and Atlantic Partners- -Proceeds to advance vapendavir, a fir...
Announces appointment of Claire M. Fraser, Ph.D., to its Board of Directors Forms a global life sciences and diagnostics leader focused on high-...
Sharp Sterile Manufacturing has announced a $28 million expansion of its site in Lee, Massachusetts. The enhanced state-of-the-art facility will st...
Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuropla...
Bavarian Nordic A/S announced its intent to launch a one-time share buy-back program of up to DKK 500 million to be executed over the next 12 month...
-Merck (NYSE: MRK), known as MSD outside the United States and Canada, has been notified that Tutanota LLC (Tutanota) has commenced an unsolicited &ldquo...
© 2026 Biopharma Boardroom. All Rights Reserved.
